## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `pt-141-glp-1`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/pt-141-glp-1/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/pt-141-glp-1/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/pt-141-glp-1/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/pt-141-glp-1/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/pt-141-glp-1/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/pt-141-glp-1/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `pt-141-glp-1` v2 · content_hash `f4b147f58b1e6e76…` · thread_head genesis · 23 DIVs
- **thesis (c1):** Two phase 3 RECONNECT trials showed bremelanotide improved sexual desire and reduced distress in premenopausal women with HSDD versus placebo (human).
  - c2 [human/active] BMT-801 phase 2 trial met primary endpoint: low-dose bremelanotide plus tirzepatide produced additive/synergistic weight loss and prevented post-tirzepatide reg
  - c3 [human/active] Case reports link GLP-1 initiation to anorgasmia that resolved on tirzepatide switch (human).
  - c4 [human/active] FAERS analysis found weak association between GLP-1 agonists and reported male sexual dysfunction (human).
  - c5 [anecdotal/active] Reddit users on GLP-1 report libido reduction and discuss PT-141 as a possible counter for the arousal layer (anecdotal).
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/pt-141-glp-1/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/pt-141-glp-1/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `pt-141-glp-1`
- **title:** PT-141 and GLP-1 Agonists: Evidence-Graded Look at Combination Use
- **url:** https://miscsubjects.com/a/pt-141-glp-1
- **register:** source_ledger
- **updated:** 2026-07-17T02:41:06.022Z
- **tags:** peptide, matrix

## Body

## What's breaking down

No single disease profile is tied to the slug, but the cross points to two overlapping layers: metabolic regulation (appetite, weight, energy balance) and central nervous system arousal pathways (sexual desire via melanocortin receptors). GLP-1 agonists primarily act on metabolic and gut signals. PT-141 targets melanocortin-4 receptors (MC4R) in the brain. When these layers interact, the question becomes whether one pathway supports or trades off against the other.

## Why PT-141 might help you

PT-141 (bremelanotide) is discussed for the sexual / CNS arousal layer. If that layer is part of your problem while using GLP-1 agonists, the compound is examined because it engages central melanocortin pathways that influence desire and arousal rather than masking symptoms. Step one: MC4R activation occurs in brain regions tied to reward and sexual response. Step two: this occurs independently of blood-flow mechanisms used by PDE5 inhibitors. Step three: therefore, if GLP-1 use coincides with reduced desire reports, PT-141 is studied for its distinct central action on that specific layer.

## Why GLP-1 agonists (class) matters for you

GLP-1 agonists support metabolism through appetite reduction and improved glycemic control. This can reduce overall body weight, which in turn lowers mechanical stress on joints and the spine in weight-sensitive individuals. At the same time, rapid weight loss carries tradeoffs such as potential muscle loss or gut slowing. The class therefore primarily supports metabolic repair pathways while suppressing hunger signals. Whether this helps or trades off against other layers depends on the individual balance between sustained weight reduction and any reported shifts in energy or desire.

## How these fit together

Single-compound focus applies here. PT-141 targets the sexual / CNS arousal layer through MC4R agonism. GLP-1 agonists target metabolic layers. The two do not overlap in primary mechanism, so any combined use would map to separate degeneration layers without repetition: metabolic support from the agonist plus central arousal support from PT-141 if needed. Recent human data on co-administration for obesity showed additive effects on weight loss without added safety signals in the tested regimen.

## What the evidence actually shows

Human data exist for both compounds separately and in limited combination. Two identical phase 3 randomized double-blind placebo-controlled trials (RECONNECT) in premenopausal women with hypoactive sexual desire disorder found bremelanotide 1.75 mg subcutaneous as-needed produced statistically significant gains in sexual desire scores and reductions in distress versus placebo over 24 weeks (human tier). Nausea, flushing, and headache occurred more frequently with the drug. A phase 2 randomized double-blind placebo-controlled trial (BMT-801) of bremelanotide co-administered with tirzepatide met its primary endpoint for weight loss, showed additive and synergistic weight reduction at low doses, and indicated the melanocortin agonist halted rapid weight regain after tirzepatide cessation; co-administration did not increase tolerability or safety issues (human tier, 2025).

GLP-1 agonist effects on sexual function show mixed human signals. Case reports document anorgasmia onset shortly after starting liraglutide or semaglutide that resolved after switching to tirzepatide. FAERS database analysis identified 182 reports of male sexual dysfunction (orgasmic dysfunction, erectile dysfunction, decreased libido) with various GLP-1 agonists, though disproportionality measures indicated only a weak association. Some observational and survey data note both increased and decreased desire after GLP-1 initiation, often linked to weight change or side effects. No large dedicated human trials examine PT-141 specifically for GLP-1-related sexual changes.

Preclinical data are limited in the returned results. Animal models originally supported melanocortin effects on sexual behavior, but human translation is the stronger evidence tier here.

Anecdotal reports appear on forums but remain low-tier evidence.

## What scientists say

Palatin Technologies reported the BMT-801 phase 2 results as exceeding expectations, with co-administration described as additive and synergistic for weight loss and safe at the doses tested. Phase 3 RECONNECT investigators concluded bremelanotide significantly improved desire and reduced distress in the target population.

## What people say on Reddit

Users on GLP-1 threads frequently describe lowered libido or desire after starting semaglutide or tirzepatide and mention PT-141 as a compound some consider to address that specific layer. Reports note variable response, with some stating it works for arousal even when other approaches do not. Dosing discussions and individual experiences vary widely; these remain anecdotal.

## What people say on X

Public posts on X mirror forum patterns: occasional mentions of combining the two for weight or desire goals, with limited detail on outcomes. No high-volume verified threads dominate recent results.

## What we do not know

Long-term human data on the specific PT-141 plus GLP-1 combination beyond the 8-week phase 2 obesity signal are absent. Optimal dosing, durability of any sexual-function benefit in GLP-1 users, effects on muscle preservation or other tradeoffs, and performance in broader populations (including men or postmenopausal women) remain untested in large trials. Mechanisms linking GLP-1 to any sexual changes are still theoretical in most reports.

## Safety and limits

PT-141 carries known side effects including nausea, flushing, and headache in human trials. Blood-pressure increases have been noted in some contexts. GLP-1 agonists have established gastrointestinal and other class effects. The phase 2 combination study reported no increase in safety or tolerability issues at the doses used, but this does not establish long-term safety or generalizability. All evidence must be weighed against individual health status; no compound replaces medical evaluation.

## Claims (5)

- **c1** [human w=0.8] Two phase 3 RECONNECT trials showed bremelanotide improved sexual desire and reduced distress in premenopausal women with HSDD versus placebo (human).
  - who_claims: grok/grok-4.3
  - sources: s1
- **c2** [human w=0.8] BMT-801 phase 2 trial met primary endpoint: low-dose bremelanotide plus tirzepatide produced additive/synergistic weight loss and prevented post-tirzepatide regain without added safety signals (human, 2025).
  - who_claims: grok/grok-4.3
  - sources: s9
- **c3** [human w=0.8] Case reports link GLP-1 initiation to anorgasmia that resolved on tirzepatide switch (human).
  - who_claims: grok/grok-4.3
  - sources: s14
- **c4** [human w=0.8] FAERS analysis found weak association between GLP-1 agonists and reported male sexual dysfunction (human).
  - who_claims: grok/grok-4.3
  - sources: s30
- **c5** [anecdotal w=0.3] Reddit users on GLP-1 report libido reduction and discuss PT-141 as a possible counter for the arousal layer (anecdotal).
  - who_claims: grok/grok-4.3
  - sources: s33

## Voxel graph (5 atoms · 10 edges)
- full graph: https://miscsubjects.com/api/articles/pt-141-glp-1/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (5)
- chain valid: yes · head: `cc533e66f90b3072`

### s1 · pubmed · ok
- title: Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder
- url: https://pubmed.ncbi.nlm.nih.gov/31599840/
- summary: Phase 3 RECONNECT trials results.
- quote: Both studies demonstrated that bremelanotide significantly improved sexual desire and related distress in premenopausal women with hypoactive sexual desire disorder.
- claim_ids: c1
- hash: `55e0355b8877a219`

### s9 · news · ok
- title: Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study
- url: https://palatin.com/press_releases/palatin-announces-mc4r-agonist-bremelanotide-co-administered-with-glp-1-gip-tirzepatide-meets-primary-endpoint-in-phase-2-obesity-study/
- summary: Phase 2 combination trial topline.
- quote: The data demonstrated that co-administration was additive and synergistic, resulting in increased weight loss, and that co-administration did not result in increased tolerability or safety issues for patients.
- claim_ids: c2
- hash: `76bfcde06e1c2bf4`

### s14 · pubmed · ok
- title: Anorgasmia following initiation of GLP-1 agonist
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC12260840/
- summary: Case of GLP-1 linked anorgasmia.
- quote: Within 2 weeks of initiating the medication, she noticed a change in her sexual function, specifically anorgasmia.
- claim_ids: c3
- hash: `ae9f8a74f6b45364`

### s30 · pubmed · ok
- title: Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data
- url: https://pubmed.ncbi.nlm.nih.gov/40240532/
- summary: FAERS disproportionality analysis.
- quote: low ROR (0.41... ) suggest a weak association.
- claim_ids: c4
- hash: `a0c79fa14d9555ba`

### s33 · reddit · ok
- title: Are GLP-1 Medications Affecting Your Libido?
- url: https://www.reddit.com/r/glp1/comments/1i6khhz/are_glp1_medications_affecting_your_libido_a/
- summary: User reports of libido change on GLP-1.
- quote: They all lowered my craving for sex. By a lot.
- claim_ids: c5
- hash: `cc533e66f90b3072`

## Provenance (2 model passes)
- chain valid: yes · head: `faa3ed588a86463a`

- write · grok/grok-4.3 · 2026-06-30T01:17 · hash `1c33a9cc3779`
- voxel_divide · owner · 2026-07-17T02:41 · hash `faa3ed588a86`

## Question graph
- questions: 0 · evidence ingests: 0

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/pt-141-glp-1/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/pt-141-glp-1/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"pt-141-glp-1","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest pt-141-glp-1|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim pt-141-glp-1|tier|assertion`
- **iMessage ask:** `pt-141-glp-1|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `pt-141-glp-1`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/pt-141-glp-1/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/pt-141-glp-1/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*